STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: Sustained activation of ERK with improved growth inhibition

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 403-411

  Sheu, Lai Fa ^a,b   Young, Zuei How ^b   Lee, Wen Cheng ^b   Chen, Yu Fang ^b   Kao, Woei Yau ^a   Chen, Ann ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cisplatin; Cytotoxicity; ERK; Nasopharyngeal carcinoma cells; STI571

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CARCINOMA; CELL DEATH; CELL PROLIFERATION; ENZYME ACTIVATION; HUMAN; IC 50; MALE; METABOLISM; MOUSE; NASOPHARYNX TUMOR; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL DEATH; CELL PROLIFERATION; CISPLATIN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES;

EID: 34047267493     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
2. Blume-Jensen P and Hunter T: Oncogenic kinase signaling. Nature 411: 355-365, 2001.
3. Lee AV, Schiff R, Cui X, et al: New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res 9: S516-S523, 2003.
4. Manley PW, Cowan-Jacob SW, Buchdunger E, et al: Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38 (Suppl 5): 19-27, 2002.
5. Kurzrock R, Kantarjian HM, Druker BJ and Talpaz M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 38: 819-830, 2003.
6. Kawaguchi Y, Jinnai I, Nagai K, et al: Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCRABL-positive acute lymphoblastic leukemia cells. Leukemia 15: 590-594, 2001.
7. Buchdunger E, O'Reilly T and Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 38 (Suppl 5): 28-36, 2002.
8. Sjoblom T, Shimizu A, O'Brien KP, et al: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.
9. Kilic T, Alberta JA, Zdunek PR, et al: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150, 2000.
10. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470, 2003.
11. Trempat P, Villalva C, Laurent G, et al: Chronic myelo-proliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 22: 5702-5706, 2003. (Pubitemid 37102707)
12. Daniels CE, Wilkes MC, Edens M, et al: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316, 2004.
13. Yoshiji H, Noguchi R, Kuriyama S, et al: Imatinib mesylate (STI571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288: G907-G913, 2005.
14. Beham-Schmid C, Apfelbeck U, Sill H, et al: Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99: 381-383, 2002.
15. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutation of c-kit in human gastrointestinal stromal tumor. Science 279: 577-580, 1998. (Pubitemid 28067289)
16. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058, 2001.
17. Eisenberg BL and Judson I: Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11: 465-475, 2004.
18. Zermati Y, De Sepulveda P, Feger F, et al: Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660-664, 2003.
19. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000. (Pubitemid 30637763)
20. Wang WL, Healy ME, Sattler M, et al: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 9: 3521-3528, 2000. (Pubitemid 30487449)
21. Merchant MS, Woo CW, Mackall CL and Thiele CJ: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 94: 1673-1679, 2002.
22. Scotlandi K, Manara MC, Strammiello R, et al: C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21: 1952-1960, 2003.
23. Attoub S, Rivat C, Rodrigues S, et al: The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62: 4879-4883, 2002.
24. Topaly J, Zeller WJ and Fruehauf S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15: 342-347, 2001.
25. Krystal GW: Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 4: 16-21, 2001.
26. Sheu LF, Lee WC, Lee HS, Kao WY and Chen A: Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium. J Pathol 207: 216-223, 2005.
27. Sheu LF, Chen A, Lee HS, Hsu HY and Yu DS: Cooperative interactions among p53, bcl-2, and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol Int 54: 475-485, 2004.
28. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A and Boyd MR: Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515-2520, 1991.
29. Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443, 2000.
30. Moodie SA and Wolfman A: The 3Rs of life: Ras, Raf and growth regulation. Trends Genet 10: 44-48, 1994.
31. 2. Role in cell survival following oxidant injury. J Biol Chem 271: 4138-4142, 1996.
32. 2. Am J Physiol 273: L1029-L1035, 1997.
33. Kim YK, Kim HJ, Kwon CH, et al: Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25: 374-382, 2005.
34. Choi BK, Choi CH, Oh HL and Kim YK: Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology 25: 915-924, 2004. (Pubitemid 39335584)
35. Li DW, Liu JP, Mao YW, et al: Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell 16: 4437-4453, 2005.
36. Persons DL, Yazlovitskaya EM, Cui W and Pelling JC: Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5: 1007-1014, 1999. (Pubitemid 29233214)
37. Yu C, Rahmani M, Almenara J, Sausville EA, Dent P and Grant S: Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and Akt-dependent process. Oncogene 23: 1364-1376, 2004. (Pubitemid 38406832)
38. Miglietta A, Bozzo F, Bocca C, et al: Conjugated linoleic acid induces apoptosis in MDA-MB-231 breast cancer cells through ERK/MAPK signaling and mitochondrial pathway. Cancer Lett 234: 149-157, 2006.
39. Te Kronnie G, Timeus F, Rinaldi A, et al: Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-kit inhibition. Int J Mol Med 14: 373-382, 2004.
40. Decaudin D, De Cremoux P, Sastre X, et al: In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 113: 849-856, 2005.
41. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N and San Miguel JF: Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 123: 858-868, 2003. (Pubitemid 37533298)
42. Mow BM, Chandra J, Svingen PA, et al: Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99: 664-671, 2002. (Pubitemid 34533106)
43. Salomon AR, Ficarro SB, Brill LM, et al: Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci USA 100: 443-448, 2003.
44. Wolff NC, Randle DE, Egorin MJ, Minna JD and Ilaria RL Jr: Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 10: 3528-3534, 2004.
45. Gonzalez I, Andreu EJ, Panizo A, et al: Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 10: 751-761, 2004. (Pubitemid 38174013)
46. Radujkovic A, Schad M, Topaly J, et al: Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG. Leukemia 19: 1198-1206, 2005. (Pubitemid 40946004)
47. Tseng PH, Lin HP, Zhu J, et al: Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 105: 4021-4027, 2005. (Pubitemid 40656151)
48. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104: 3507-3512, 2004.
49. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y and Toge T: Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103: 1800-1809, 2005.
50. Kim SJ, Uehara H, Yazici S, et al: Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 65: 3707-3715, 2005.
51. O'Reilly T, Wartmann M, Maira SM, et al: Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 55: 307-317, 2005.
52. Bruce IA, Slevin NJ, Homer JJ, McGown AT and Ward TH: Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 16: 719-726, 2005.
53. Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA and Panasci L: Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18: 409-414, 2004.
54. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
55. Pietras K, Ostman A, Sjoquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001.
56. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K and Okada M: Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 279: 18600-18607, 2004.
57. Borg C, Terme M, Taieb J, et al: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388, 2004.
58. Rochat B: Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44: 349-366, 2005.